Post hoc analysis of 1648 HFpEF patients in TOPCAT Americas: an early eGFR dip (≥15% by week 4) was more common with spironolactone than placebo (33% vs 20%) and was associated with worse outcomes, but spironolactone's effect did not differ by dip (P interaction .81).
Secondary analysisn = 1,648
Beldhuis et al. Spironolactone, early acute eGFR changes, and clinical outcomes in patients with heart failure with preserved ejection fraction: insights from TOPCAT Americas